A A A A A
AAnurseAworkingAinAradiologyAadministersAiodineAtoAaApatientAwhoAisAhavingAaAcomputedAtomographyA(C
T)Ascan.ATheAnurseAworkingAonAtheAoncologyAunitAadministersAchemotherapyAtoApatientsAwhoAhave
Acancer.AAtAtheAPublicAHealthADepartment,AaAnurseAadministersAaAmeasles-mumps-
rubellaA(MMR)AvaccineAtoAaA14-month-
oldAchildAasAaAroutineAimmunization.AWhichAbranchAofApharmacologyAbestAdescribesAtheAactionsAof
AallAthreeAnurses?
PharmacoeconomicsA
Pharmacotherapeutics
PharmacodynamicsAP
A
harmacokineticsA Ans:
B
Response:
PharmacologyAisAtheAstudyAofAtheAbiologicAeffectsAofAchemicals.ANursesAareAinvolvedAwithAclinicalAph
armacologyAorApharmacotherapeutics,AwhichAisAaAbranchAofApharmacologyAthatAdealsAwithAtheAusesAofA
drugsAtoAtreat,Aprevent,AandAdiagnoseAdisease.ATheAradiologyAnurseAisAadministeringAaAdrugAtoAhelpAdi
agnoseAaAdisease.ATheAoncologyAnurseAisAadministeringAaAdrugAtoAhelpAtreatAaAdisease.
PharmacoeconomicsAincludesAanyAcostsAinvolvedAinAdrugAtherapy.APharmacodynamicsAinvolvesAhowAa
AdrugAaffectsAtheAbodyAandApharmacokineticsAisAhowAtheAbodyAactsAonAtheAbody.
AAphysicianAhasAorderedAintramuscularA(IM)AinjectionsAofAmorphine,AaAnarcotic,AeveryA4AhoursAasAneededAf
orApainAinAaAmotorAvehicleAaccidentAvictim.ATheAnurseAisAawareAthisAdrugAhasAaAhighAabuseApotential
.
UnderAwhatAcategoryAwouldAmorphineAbeAclassified?
ScheduleAIAS
cheduleAIIAS
cheduleAIIIA
ScheduleAIV
Ans:
A B
Response:
NarcoticsAwithAaAhighAabuseApotentialAareAclassifiedAasAScheduleAIIAdrugsAbecauseAofAsevereAdependence
, liability.AScheduleAIAdrugsAhaveAhighAabuseApotentialAandAnoAacceptedAmedicalAuse.AScheduleAIIIAdr
ugsAhaveAaAlesserAabuseApotentialAthanAIIAandAanAacceptedAmedicalAuse.AScheduleAIVAdrugsAhaveAlo
wAabuseApotentialAandAlimitedAdependenceAliability.
WhenAinvolvedAinAphaseAIIIAdrugAevaluationAstudies,AwhatAresponsibilitiesAwouldAtheAnurseAhav
e?AWorkingAwithAanimalsAwhoAareAgivenAexperimentalAdrugs
ChoosingAappropriateApatientsAtoAbeAinvolvedAinAtheAdrugAstudyAMon
itoringAandAobservingApatientsAcloselyAforAadverseAeffectsAConductin
gAresearchAtoAdetermineAeffectivenessAofAtheAdrugAAns:AC
Response:
PhaseAIIIAstudiesAinvolveAuseAofAaAdrugAinAaAvastAclinicalApopulationAinAwhichApatientsAareAaskedAtoAre
cordAanyAsymptomsAtheyAexperienceAwhileAtakingAtheAdrugs.ANursesAmayAbeAresponsibleAforAhelpingAc
ollectAandAanalyzeAtheAinformationAtoAbeAsharedAwithAtheAFoodAandADrugAAdministrationA(FDA)AbutA
wouldAnotAconductAresearchAindependentlyAbecauseAnursesAdoAnotAprescribeAmedications.AUseAofAanim
alsAinAdrugAtestingAisAdoneAinAtheApreclinicalAtrials.ASelectApatientsAwhoAareAinvolvedAinAphaseAIIAstudi
esAtoAparticipateAinAstudiesAwhereAtheAparticipantsAhaveAtheAdiseaseAtheAdrugAisAintendedAtoAtreat.AThes
eApatientsAareAmonitoredAcloselyAforAdrugAactionAandAadverseAeffects.APhaseAIAstudiesAinvolveAhealthyA
humanAvolunteersAwhoAareAusuallyApaidAforAtheirAparticipation.ANursesAmayAobserveAforAadverseAeffec
tsAandAtoxicity.
WhatAconceptAisAconsideredAwhenAgenericAdrugsAareAsubstitutedAforAbrandAnameAdrugs?ABioavai
lability
CriticalAconcentration
Distribution
A
Half-
lifeA Ans: A
Response:
BioavailabilityAisAtheAportionAofAaAdoseAofAaAdrugAthatAreachesAtheAsystemicAcirculationAandAisAavaila
bleAtoAactAonAbodyAcells.ABindersAusedAinAaAgenericAdrugAmayAnotAbeAtheAsameAasAthoseAusedAinAtheA
brandAnameAdrug.ATherefore,AtheAwayAtheAbodyAbreaksAdownAandAusesAtheAdrugAmayAdiffer,AwhichA
mayAeliminateAaAgenericAdrugAsubstitution.ACriticalAconcentrationAisAtheAamountAofAaAdrugAthatAisAne
ededAtoAcauseAaAtherapeuticAeffectAandAshouldAnotAdifferAbetweenAgenericAandAbrandAnameAmedicati
ons.
DistributionAisAtheAphaseAofApharmacokinetics,AwhichAinvolvesAtheAmovementAofAaAdrugAtoAtheAbod
y’sAtissuesAandAisAthe
, sameAinAgenericAandAbrandAnameAdrugs.AAAdrug’sAhalf-
lifeAisAtheAtimeAitAtakesAforAtheAamountAofAdrugAtoAdecreaseAtoAhalfAtheApeakAlevel,AwhichAshouldAnotAc
hangeAwhenAsubstitutingAaAgenericAmedication.
AAnurseAisAassessingAtheApatient’sAhomeAmedicationAuse.AAfterAlisteningAtoAtheApatientAlistAcurrentAmedicat
ions,AtheAnurseAasksAwhatApriorityAquestion?
DoAyouAtakeAanyAgenericAmedications?
AreAanyAofAtheseAmedicationsAorphanAdrugs?
AreAtheseAmedicationsAsafeAtoAtakeAduringApregnancy?A
DoAyouAtakeAanyAover-the-counterAmedications?
Ans: D
Response:
ItAisAimportantAforAtheAnurseAtoAspecificallyAquestionAuseAofAover-the-
counterAmedicationsAbecauseApatientsAmayAnotAconsiderAthemAimportant.ATheApatientAisAunlikelyAtoAkn
owAtheAmeaningAofAorphanAdrugsAunlessAtheyAtooAareAhealthAcareAproviders.ASafetyAduringApregnancy,
AuseAofAaAgenericAmedication,AorAclassificationAofAorphanAdrugsAareAthingsAtheApatientAwouldAbeAunabl
eAtoAanswerAbutAcouldAbeAfoundAinAreferenceAbooksAifAtheAnurseAwishesAtoAresearchAthem.
AfterAcompletingAaAcourseAonApharmacologyAforAnurses,AwhatAwillAtheAnurseAknow?AEver
ythingAnecessaryAforAsafeAandAeffectiveAmedicationAadministration
CurrentApharmacologicAtherapy;AtheAnurseAwillAnotArequireAongoingAeducationAforA5Ayears
.AGeneralAdrugAinformation;AtheAnurseAcanAconsultAaAdrugAguideAforAspecificAdrugAinforma
tion.ATheAdrugAactionsAthatAareAassociatedAwithAeachAclassificationAofAmedicationAAns: C
Response:
AfterAcompletingAaApharmacologyAcourseAnursesAwillAhaveAgeneralAdrugAinformationAneededAforAsafeA
andAeffectiveAmedicationAadministrationAbutAwillAneedAtoAconsultAaAdrugAguideAforAspecificAdrugAinfor
mationAbeforeAadministeringAanyAmedication.APharmacologyAisAconstantlyAchanging,AwithAnewAdrugsA
enteringA theAmarketAandAnewAusesAforAexistingAdrugsAidentified.AContinuingAeducationAinApharmacolo
gyAisAessentialAtoAsafeApractice.ANursesAtendAtoAbecomeAfamiliarAwithAtheAmedicationsAtheyAadminister
AmostAoften,AbutAthereAwillAalwaysAbeAaAneedAtoAresearchAnewAdrugsAandAalsoAthoseAtheAnurseAisAnotAfa
miliarAwithAbecauseAnoAnurseAknowsAallAmedications.